Zydus Lifesciences bags USFDA nod for Ivermectin Cream for treatment of inflammatory lesions of rosacea
Ivermectin Cream is used for the treatment of inflammatory lesions of rosacea.
Ahmedabad: Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ivermectin Cream, 1%. USRLD: Soolantra.
Ivermectin Cream is used for the treatment of inflammatory lesions of rosacea. The drug will be manufactured at the group's topical manufacturing facility at Ahmedabad, India.
Ivermectin Cream had annual sales of USD 176 million in the United States according to IQVIA data (IQVIA MAT June 2022).
The group now has 319 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Life Desidustat gets CDSCO panel nod to treat Anaemia in Kidney Patients
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the manufacture of generic drugs.
Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Next Story